Insmed Incorporated

NASDAQ:INSM

Biotechnology

Healthcare
$119.80 -2.77%

-$2.73 today

Market cap
$26.28B
Beta
0.77
P/E (TTM)
-17.4
EPS (TTM)
-$5.49
52W Low $90.39High $212.75

Volume 1.94M

Average 3.31M

INSM Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Insmed IncorporatedNASDAQ: INSM

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q2 FY2026 weighted avg shares (diluted) of 217.35M shares rose 14.8% year over year, behind the +18.7% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at +20.2% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +14.8% toward the trailing-twelve-month pace of +18.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
217.35M+0.9% QoQ
Last fiscal yearDec 2025
213.64M+30.2% YoY
LTMJun 2026
214.47M+18.7% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.8%——
1 year+30.2%——
3-year CAGR+20.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
213.64M USD
Year-over-year change
+30.2%
4-year CAGR
+17.5%

Weighted Avg Shares (Diluted) vs competitors

How INSM compares with its peers on the latest reported figures

  • INSM's LTM Jun 2026 weighted avg shares (diluted) of 214.47M shares is the highest of the 4 companies compared; the peer median is 51.74M shares.
  • Its year-over-year change of +18.7% is the highest of 4, against a peer median of +5.2%.
  • Over three fiscal years its annual growth of +20.2% compares with a peer median of -0.4%.
INSM Competitors Peer median
Weighted Avg Shares (Diluted) for INSM and competitors
Company Period LTM YoY 3-year CAGR
INSMInsmed IncorporatedLTM Jun 2026214.47M +18.7%+20.2%
LQDALiquidia CorporationLTM Jun 202697.22M +16.5%+12.2%
TBPHTheravance Biopharma, Inc.LTM Mar 202651.74M +5.2%-11.2%
UTHRUnited Therapeutics CorporationLTM Jun 202647.05M -3.0%-0.4%
AVLNAvalyn Pharma Inc. Common Stock—— ——
Peer median (excluding INSM) 51.74M+5.2%-0.4%

Competitors are the stored peer set for INSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue188.46M245.36M305.21M363.71M606.42M
Cost of Revenue44.15M55.13M65.57M85.74M124.88M
Gross Profit144.31M190.23M239.64M277.97M481.55M
Gross Margin76.6%77.5%78.5%76.4%79.4%
Research & Development272.74M397.52M571.01M598.37M771.09M
Selling, General & Admin234.27M265.78M344.5M461.12M701.17M
Operating Expenses519.4M647.55M949.26M1.16B1.66B
Depreciation & Amortization14.18M10.33M10.58M11.01M16.45M
EBITDA(383.65M)(447.37M)(660.18M)(818.79M)(1.17B)
EBITDA Margin-203.6%-182.3%-216.3%-225.1%-193.2%
Operating Income(375.09M)(457.32M)(709.63M)(878.25M)(1.18B)
Operating Margin-199.0%-186.4%-232.5%-241.5%-194.0%
Interest Income174K11.08M42.13M53.31M60.66M
Interest Expense40.47M26.45M81.69M84.91M83.8M
Other Income / Expenses(61.32M)(22.83M)(37.39M)(31.81M)(95.02M)
Income Before Tax(436.41M)(480.15M)(747.01M)(910.07M)(1.27B)
Pre-Tax Margin-231.6%-195.7%-244.8%-250.2%-209.7%
Income Tax Expense(1.76M)1.38M2.56M3.71M5.03M
Net Income(434.65M)(481.53M)(749.57M)(913.77M)(1.28B)
Net Margin-230.6%-196.3%-245.6%-251.2%-210.5%
EPS (Basic)(3.88)(3.91)(5.34)(5.57)(6.41)
EPS (Diluted)(3.88)(3.91)(5.34)(5.57)(6.41)
Weighted Avg Shares112.11M123.04M140.43M164.04M213.64M
Weighted Avg Shares (Diluted)112.11M123.04M140.43M164.04M213.64M

Insmed Incorporated

NASDAQ:INSM

Intrinsic Alpha fair value

Locked

Current Price

$119.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.